Biotech
27 August 2026 Dozens of new and revised guidances could make it faster and less costly to bring generics to market, as the US ramps up pressure on drug prices.
24 August 2026
20 August 2026
More News
29 July 2026 Dealmaking is at a record pace, but not every asset is in play. So what are the therapy areas commanding the fiercest bidding wars and what’s to come?
27 July 2026 With billions in revenue set to disappear as patents expire, pharmaceutical giants are racing to acquire their way out of trouble. But are there other drivers behind the surge—and how long can the momentum last?
27 July 2026 The firm has added partners with expertise in life sciences, technology disputes and trademark strategy, alongside leadership changes at its Hong Kong affiliate.
21 July 2026 Now a Danaher subsidiary, the company is contesting a number of orders after a California court finalised several aspects of the high-profile dispute.
20 July 2026 The biotech company has launched a trio of lawsuits against two vaccine makers, while announcing receipt of a $178 million sum from Moderna under a previous deal.
17 July 2026 Blockbuster acquisitions are back, impacting the pharma industry at record pace. As billions flow into breakthrough science, LSIPR’s series explores what’s driving the surge, how today’s deals are done, and where IP comes into the picture.
16 July 2026 A Munich court ruled that Illumina infringed a rival’s DNA sequencing patents, handing the challenger an early victory in a dispute that is playing out across Europe and the US.
Latest Features
Pharma
Canada has firmly slammed the door on patenting methods of medical treatment—but the battle over what counts as a "medical method" is only just beginning. Scott MacKendrick of ROBIC examines a landmark decision that leaves the door ajar for future litigation over complex drug-dosing regimens.
Europe
A number of ongoing legislative processes are likely to significantly impact the life sciences industry this year, writes Jackie Mulryne of Morgan Lewis.
Americas
Companies that integrate data rights into their IP strategy with a holistic approach will lead in innovation while minimising risk, says Terri Shieh-Newton of Mintz.
Americas
In the complex world of bsAb patenting, counsel need to turn chefs to serve up success. Benjamin Pelletier of Haynes Boone puts together a menu of dos and don’ts.
Europe
As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.
Americas
In the second of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax delve into the real reasons why medicine costs more in the US.
Americas
In the first of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax explore how legislative, judicial, and executive policies have dramatically altered the risks for drug innovation.
Biotech
Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox